Valuation: VolitionRx Limited

Market Cap 11.66M 10.2M 9.37M 8.73M 16.56M 1.11B 16.82M 112M 43.73M 546M 43.78M 42.84M 1.88B P/E 2026 *
-0.63x
P/E 2027 * -1.01x
Enterprise Value 11.66M 10.2M 9.37M 8.73M 16.56M 1.11B 16.82M 112M 43.73M 546M 43.78M 42.84M 1.88B EV / Sales 2026 *
4.71x
EV / Sales 2027 * 2.03x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day+2.94%
1 week+9.38%
Current month+3.70%
1 month-30.00%
3 months-59.18%
6 months-74.36%
Current year-72.61%
1 week 1.27
Extreme 1.27
1.46
1 month 1.17
Extreme 1.17
1.56
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Chairman 61 05/11/2024
Director/Board Member 55 05/10/2011
Director/Board Member - 29/09/2024
Date Insider Type Main position Quantity % Market Cap.
03-16Tax

Chief Technology Officer

5,310 0.0039%
03-16
Concord International, Inc.
OtherCompany 0 0%
03-16Tax

Company Secretary

3,948 0.0029%
Change 5-day change 1-year change 3-year change Capi.($)
+2.94%+9.38%-90.54%-95.04% 11.66M
-4.63%-5.64%+107.49%+129.05% 4.55B
-5.27%+1.10%+79.58%+217.22% 3.39B
+2.15%+5.68%-25.44%-39.45% 2.07B
+8.56%+1.41%+146.29%-39.30% 1.92B
-0.21%+1.28%+51.72%+243.82% 1.51B
-1.79%-2.89%+126.22%-51.45% 891M
+1.38%+4.82%-8.85%+41.45% 874M
+2.32%+6.54%-34.61%-16.56% 498M
-0.83%+8.52%+3.06% - 473M
Average +0.46%+1.25%+35.49%+43.30% 1.62B
Weighted average by Cap. -1.11%+0.93%+71.26%+96.40%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 1.99M 1.86M 3.52M 236M 3.57M 23.9M 9.29M 116M 9.3M 9.1M 400M 5.73M 5.01M 4.61M 4.29M 8.14M 546M 8.27M 55.3M 21.5M 268M 21.52M 21.06M 925M
Net income -22.2M -19.41M -17.84M -16.63M -31.54M -2.11B -32.01M -214M -83.25M -1.04B -83.34M -81.55M -3.58B -19.62M -17.15M -15.76M -14.69M -27.87M -1.87B -28.29M -189M -73.56M -918M -73.64M -72.06M -3.16B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
02/07/26 US$1.400 +2.94% 208,730
01/07/26 US$1.360 +0.74% 201,077
30/06/26 US$1.350 -4.93% 163,419
29/06/26 US$1.420 +10.94% 301,479
26/06/26 US$1.280 -0.78% 122,605
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.400USD
Average target price
16.97USD
Spread / Average Target
+1,111.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock